Incruse Ellipta is Now Available

On April 30, 2014, the United States Food and Drug Administration approved umeclidinium (brand name: Incruse Ellipta) as a once-daily inhaled bronchodilator for treatment of those with COPD, including chronic bronchitis and emphysema. As of January 2015, this medication is available in US pharmacies.

Incruse Ellipta is a once-daily dry powder bronchodilator

Incruse Ellipta is a once-daily dry powder bronchodilator

Incruse Ellipta is in the class of bronchodilators called long-acting muscarinic antagonists (LAMA).  Other approved medications in this class are tiotropium (brand name: Spiriva HandiHaler and Respimat) and aclidinium (brand name: Tudorza Pressair). These medications open the airways and make it easier to breathe by blocking a receptor in the muscles that wrap around breathing tubes.

Picture of Spiriva Respimat mist bronchodilator

Spiriva Respimat is a once daily bronchodilator that delivers a mist

 

Tudorza Pressair is a twice daily dry powder bronchodilator

Tudorza Pressair is a twice daily dry powder bronchodilator

 

Information about the bronchodilator (called the package insert) states that Incruse Ellipta should be used with caution in those with narrow-angle glaucoma and with urinary retention due to enlargement of the prostate. The most common reported side effect in studies was nasopharyngitis (irritation of nose and throat). Also, you should not take this medication if you are using Spiriva or Tudorza as they are the same type of brocnhodilators.

As always, you should discuss any new medication with your doctor.

Umeclidinium (Incruse Ellipta) approved for COPD

GOOD NEWS! Umeclidinium approved to treat COPD.

On April 30, 2014, The United States Food and Drug Administration (FDA) approved a new bronchodilator called umeclidinium (brand name is Incruse™ Ellipta™). This dry powder medication is approved for once-daily maintenance treatment for patients with COPD including both chronic bronchitis and emphysema.  The approved dose is 62.5 mcg.  The approval was based on study results in over 2,500 patients with COPD and follows approval of this medication in Canada and Europe.

This medication belongs to the class of bronchodilators called a long-acting muscarinic antagonist (LAMA) and is similar to the once daily tiotropium (brand name: Spiriva™ HandiHaler™) and twice daily aclidinium (brand name: Tudorza™ Pressair™). As these three LAMA medications are the same class, you should only use of these bronchodilators at a time.

GlaxoSmithKline, the pharmaceutical company that makes Incruse™ Ellipta™, reported that the most common side effects are nasopharyngitis, upper respiratory tract infection, cough, and joint pain. The company warned that the medication should not be used if you have narrow-angle glaucoma or have problems with urination. GlaxoSmithKline plans to launch the medication in the US toward the end of 2014.